To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).

Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).

On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).

On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).